An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Robert F. Kennedy Jr. pushed for expanded access to controversial peptides, calling for slackened rules. The vote reflects a broader shift in how regulators view specialty peptide therapies, which have drawn growing interest from patients seeking alternatives to traditional drugs. Researchers say peptide treatments could reshape approaches to difficult infections, though concerns about consistency persist. The committee's endorsement of four peptides opens the door for more broad prescribing, even as skeptics warn of limited evidence. Industry analysts note that peptide-focused companies may see increased investor attention following the panel's decision. The rejection of emideltide, meanwhile, highlights the FDA's cautious stance on certain peptide candidates.